| Market Cap | ₹6,303.29 CrMid-cap |
|---|---|
| Revenue TTM | ₹851.48 CrOperating Revenue |
| ROE Annual | 47.49%High Efficiency |
| PE TTM | 26.65Sector PE 49.75 |
Key highlights
- Introduction of Acharya Ji's Amrit Tattava Vati and Acharya Ji's Oja Amrit Vati
- Both products are launched as 60-tablet units specifically for the domestic market
- Company reported a high Annual Revenue Growth of 70.21% reaching ₹801.36 Cr
- Net Profit surged by 177.51% annually, with TTM profit at ₹236.49 Cr
- JSLL maintains a robust Return on Equity (ROE) of 47.49%
The Product — What It Is
Jeena Sikho Lifecare has officially introduced two new Ayurvedic tablet formulations under its flagship brand: Acharya Ji's Amrit Tattava Vati and Acharya Ji's Oja Amrit Vati. Each product is packaged in containers of 60 tablets and is tailored for the domestic Indian market. These supplements are categorized as proprietary Ayurvedic medicines, focusing on wellness and holistic healthcare.
By transitioning traditional herbal wisdom into standardized tablet forms, the company aims to meet the modern consumer's demand for convenient, dosage-accurate wellness solutions. The launch aligns with the company's mission to provide evidence-based Ayurvedic alternatives for daily health management.
Strategic Fit
The addition of these products directly supports Jeena Sikho's integrated business model, which revolves around its network of over 120 'Shuddhi' Ayurvedic clinics and hospitals. These facilities serve as primary distribution and consultation points, allowing the company to capture the full value chain from manufacturing to patient care. The new wellness formulations complement the company's specialized treatment protocols for chronic ailments, broadening its reach into the preventative healthcare segment.
This expansion is a key component of the company's 'Freedom from 2D Diseases & Drugs' initiative, aiming to provide comprehensive Ayurvedic support across various health parameters.
Financial Context
- Operating revenue showed significant momentum with a 70.21% annual growth rate
- Net profit for the last fiscal year grew by 177.51% to reach ₹221.85 Cr
- The company maintains an operating profit margin of 41.03% as of the latest quarter
- JSLL carries a Piotroski Score of 7, indicating strong financial health and operational efficiency
- Current TTM PE of 26.65x sits below the industry average of 48.87x
Industry Context
The Indian Ayurvedic market is experiencing a significant shift toward organized players who can offer standardized and clinically documented products. Sector-wide revenue growth for pharmaceuticals and biotechnology stood at 15.53% in the recent quarter, while Jeena Sikho outperformed this with a 28.76% YoY quarterly revenue increase. Rising health consciousness and a preference for natural ingredients over synthetic alternatives continue to drive demand for wellness supplements.
The launch of the Amrit and Oja series places the company in a competitive position within the high-growth domestic wellness market, leveraging its established brand equity and expansive clinical infrastructure.
| Share price | ₹507.1 |
|---|---|
| Market capitalisation | ₹6,303.29 Cr |
| Revenue (annual) | ₹801.36 Cr |
| Net profit (annual) | ₹221.85 Cr |
| Revenue (latest quarter) | ₹224.40 Cr+4.11% vs previous quarter |
| Net profit (latest quarter) | ₹65.95 Cr+46.12% vs previous quarter |
| P/E (TTM) | 26.65×Sector 49.75× |
| Promoter holding | 63.62%0.00% QoQ |
| FII holding | 4.78%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Jeena Sikho Lifecare Limited announcing the launch of two new Ayurvedic products under Regulation 30. Market figures from a third-party data provider.
